WHO Backed Ervebo Vaccine Trial in DRC Ebola Outbreak Raises Liability Concerns

• The WHO has recommended a full-scale human trial of the Ervebo vaccine in the Democratic Republic of Congo to determine its effectiveness against the Bundibugyo strain.
• Early data from animal trials suggests that the Ervebo vaccine may offer some protection against fatal outcomes, although efficacy against symptomatic disease and transmission may be low.
• The proposed Phase III ring vaccination trial using Ervebo may provide some protection against fatal outcomes despite potentially low efficacy against symptomatic disease and transmission.
• Around 55,000 frontline workers in Ituri and North Kivu have received Ervebo through previous preventive vaccination campaigns.
• The Gavi global vaccine alliance has maintained a stockpile of 500,000 Ervebo doses, with some already available for trials in the DRC.

Expectations need to be managed about its likely protective effect if used in a Phase III ring vaccination trial as efficacy against symptomatic disease and transmission may not be high, whereas protection against a fatal outcome may be achieved.

The Democratic Republic of Congo is grappling with its largest Ebola outbreak to date, with over 4,000 confirmed cases and 1,850 deaths. The World Health Organization (WHO) has recommended a full-scale human trial of the Ervebo vaccine to determine its effectiveness against the Bundibugyo strain, which is spreading rapidly in the region. According to early data from animal trials, the Ervebo vaccine may offer some protection against this rare strain, although efficacy against symptomatic disease and transmission may be low. The WHO's Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) unanimously agreed that there are no safety concerns about using Ervebo in a clinical research study vaccinating case contacts. The experts stressed the need to manage expectations about the vaccine's likely protective effect, as it is already licensed by regulatory agencies and has been given to hundreds of thousands of people in Africa.

The proposed Phase III ring vaccination trial using Ervebo may offer some protection against fatal outcomes despite potentially low efficacy against symptomatic disease and transmission. This raises important questions for lawyers and compliance officers about the potential use of the vaccine in a clinical research study. The WHO's report highlights the need to manage expectations about the vaccine's likely protective effect, which may not be high. As the largest Ebola outbreak in DRC's history continues to unfold, it is essential to consider the legal implications of using Ervebo in a ring vaccination trial. This includes potential liability concerns and the need for informed consent from participants.

The WHO's recommendation for an Ervebo vaccine trial comes as the number of confirmed cases in DRC surpasses 4,000. The Gavi global vaccine alliance has maintained a stockpile of 500,000 Ervebo doses, with some already available for trials in the DRC. Around 55,000 frontline workers in Ituri and North Kivu have received Ervebo through previous preventive vaccination campaigns. The approved Ebola vaccine Ervebo could help reduce severe illness and deaths, particularly among frontline workers who are at high risk of exposure. As the outbreak continues to spread, it is crucial to prioritize the protection of these workers and communities.

Lawyers and compliance officers should watch for the potential use of the Ervebo vaccine in a Phase III ring vaccination trial, which may offer some protection against fatal outcomes despite potentially low efficacy against symptomatic disease and transmission.

Source: Original reporting via AP, AFP, WHO